Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Five Prime Therapeutics Inc    FPRX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
25.96(c) 25.46(c) 25.46(c) 25.76(c) 25.56(c) Last
1 284 575 917 603 530 508 614 435 409 192 Volume
-9.95% -1.93% 0.00% +1.18% -0.78% Change
More quotes
Financials ($)
Sales 2017 44,3 M
EBIT 2017 -158 M
Net income 2017 -156 M
Finance 2017 305 M
Yield 2017 -
Sales 2018 77,6 M
EBIT 2018 -142 M
Net income 2018 -140 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 9,79x
Capi. / Sales2018 9,53x
Capitalization 739 M
More Financials
Company
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics.The company advanced product candidates includes, FPA008, FPA144 and FP-1039/GSK3052230.The FPA008 is an antibody that inhibits colony stimulating... 
More about the company
Surperformance© ratings of Five Prime Therapeutics In
Trading Rating : Investor Rating :
More Ratings
Latest news on FIVE PRIME THERAPEUTICS IN
11/16 BRISTOL MYERS SQUIBB : and Five Prime Present Phase 1a/1b Data Evaluating Cabira..
11/10 Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signa..
11/10 FIVE PRIME THERAPEUTICS : `s cabira + Bristol-Myers` Opdivo shows durable clinic..
11/08 FIVE PRIME THERAPEUTICS INC : Other Events (form 8-K)
11/08 FIVE PRIME THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and..
11/08 FIVE PRIME THERAPEUTICS : to Host Conference Call on November 8 to Review Cabira..
11/07 Five Prime Therapeutics to Host Conference Call on November 11th to Review Ca..
11/06 FIVE PRIME THERAPEUTICS : posts 3Q loss
11/06 FIVE PRIME THERAPEUTICS : Management's Discussion and Analysis of Financial Cond..
11/06 FIVE PRIME THERAPEUTICS INC : Results of Operations and Financial Condition, Fin..
More news
Sector news : Bio Therapeutic Drugs
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/13 Five Prime Therapeutics (FPRX) Investor Presentation - Slideshow
11/08 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
11/08 PREMARKET GAINERS AS OF 9 : 05 am
11/08 Five Prime's cabira + Bristol-Myers' Opdivo shows durable clinical benefit in..
11/07 Midday Gainers / Losers
Chart FIVE PRIME THERAPEUTICS IN
Duration : Period :
Five Prime Therapeutics In Technical Analysis Chart | FPRX | US33830X1046 | 4-Traders
Technical analysis trends FIVE PRIME THERAPEUTICS IN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 63,1 $
Spread / Average Target 147%
EPS Revisions
Managers
NameTitle
Lewis T. Williams Chairman, President & Chief Executive Officer
Aron M. Knickerbocker Chief Operating Officer & Director
Marc L. Belsky Chief Financial Officer & Senior Vice President
Luis Borges Senior Vice President-Research
Helen Collins Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
FIVE PRIME THERAPEUTICS INC-48.99%739
GILEAD SCIENCES1.16%94 601
REGENERON PHARMACEUTICALS6.67%42 072
VERTEX PHARMACEUTICALS100.10%37 280
GENMAB3.15%11 878
EXELIXIS, INC.76.93%7 805